Estrogen pellets (14 d extended release, 0.17 mg β estradiol, Innovative Research of America) were implanted subcutaneouly into 3–4 week old female Balb/C athymic nude mice (Jackson Laboratories). Right and left inguinal mammary fatpads were injected with 106 MCF7 or MDA-MB-361 in 100 μl growth factor reduced Matrigel. Tumors were measured with calipers twice weekly. Tumor-bearing mice were randomized into treatment arms to receive fulvestrant (Novartis) delivered once weekly by intramuscular injection. All animal experimentation was performed in AAALAC approved facilities at Vanderbilt University Medical Center. All animal use protocols were reviewed and approved prior to experimentation by the Institutional Animal Care and Use Committee at Vanderbilt University, Nashville, TN.
Fulvestrant
Manufactured by Novartis
Fulvestrant is a laboratory reagent used in biomedical research. It is a selective estrogen receptor downregulator that is effective in binding and blocking estrogen receptors. The core function of Fulvestrant is to serve as a research tool to study estrogen receptor-mediated cellular processes.
Automatically generated - may contain errors
3 protocols using fulvestrant
1
Xenograft Tumor Model with Estrogen Implants
2
Treatment Strategies for Tamoxifen-Resistant Breast Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Treatment studies were performed in accordance with the French Ethics Committee as detailed in Cottu et al. 2014 (02163.01, November 2014) [25 (link)]. HBCx22 TamR were either administered tamoxifen (4 mg/kg/week); fulvestrant (50 mg/kg/week); or everolimus (Novartis Pharma), an mTOR inhibitor, orally at a dose of 2.5 mg/kg three times/week, over 100 days. Tumours harvested at the end of treatments were embedded in TMA, as described above.
3
Xenograft Tumor Model with Estrogen Implants
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Estrogen pellets (14 d extended release, 0.17 mg β estradiol, Innovative Research of America) were implanted subcutaneouly into 3–4 week old female Balb/C athymic nude mice (Jackson Laboratories). Right and left inguinal mammary fatpads were injected with 106 MCF7 or MDA-MB-361 in 100 μl growth factor reduced Matrigel. Tumors were measured with calipers twice weekly. Tumor-bearing mice were randomized into treatment arms to receive fulvestrant (Novartis) delivered once weekly by intramuscular injection. All animal experimentation was performed in AAALAC approved facilities at Vanderbilt University Medical Center. All animal use protocols were reviewed and approved prior to experimentation by the Institutional Animal Care and Use Committee at Vanderbilt University, Nashville, TN.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!